fashion -WSS

fashion

author：fashion 2025-10-01 01:49:31 - browse：54429

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Will.i.am, Britney Spears release new single, 'Mind Your Business'

WSS

Marvel Studios reveals new trailer for 'The Marvels': Watch here

There's an unseen cost to disruptive road

Maisha Meds is a PBM, but don't call it that

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

Future doctors need a strong humanities education

7 of the most gruesome medical devices in history

focus

fashion

hotspot

How one medical school became remarkably diverse

There's an unseen cost to disruptive road

Activists slam private health insurers over coverage restrictions

CDC backtracks, saying fully vaccinated people can go maskless indoors

Hollywood unions extend contract negotiations for actors

There's an unseen cost to disruptive road

How to save PrEP access — and even expand it

Body of missing toddler recovered in Delaware River days after flood: Police

Medical records are filled with copy

What to know about Saharan dust affecting the US and how it can affect health

leisure time

Maisha Meds is a PBM, but don't call it that

As Taiwan prepares for anti

Maisha Meds is a PBM, but don't call it that

FDA endorses new sterilization method for medical devices

Inaction leaves children at risk from dangerous chemotherapy drug

7 of the most gruesome medical devices in history

focus

hotspot

knowledge

hotspot